Skip to main content
Top

Open Access 29-01-2025 | Baricitinib | Brief Report

Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch

Authors: Matthias Augustin, Maddalena Napolitano, Rosa Izu-Belloso, C. Elise Kleyn, Silvia Sabatino, Susanne Grond, Joaquin R. Otero-Asman, Chunyuan Liu, Ziad Reguiai, Toshifumi Nomura

Published in: Dermatology and Therapy

Login to get access

Abstract

Introduction

Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 (“BARI itch dominant”) have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.

Materials

BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks. Patients eligible for enrollment had to have BSA ≥ 10%. This post-hoc analysis focused on placebo and BARI 4 mg for patients with BSA ≤ 40% and itch NRS ≥ 7. QoL impairment was measured using a Dermatology Life Quality Index (DLQI) of ≤ 5, and functioning outcomes were assessed using the Work Productivity and Activity Impairment (WPAI) questionnaire. Data were reported descriptively. Last observation carried forward (LOCF) data were reported, excluding data collected after the first rescue therapy date or permanent study drug discontinuation. Non-responder imputation was used to account for missing data.

Results

At BL, patients with BSA ≤ 40% and itch NRS ≥ 7 had high QoL impairment. The mean DLQI score at BL for patients who received BARI 4 mg and placebo indicates a very large effect of AD on patients’ QoL. Patients who received BARI and placebo experienced a significant itch burden and reported a similar itch NRS. At week 16, 61.5% of patients treated with BARI 4 mg indicated that it had no to only a small effect on their QoL (DLQI ≤ 5), versus 24.1% for patients receiving placebo (p < 0.01). A decrease in WPAI work impairment score of − 41.6 for BARI patients and − 7.0 for placebo patients was observed at week 16 (p < 0.01). Patients receiving BARI also observed a noticeable improvement in WPAI daily activity impairment of − 30.4 from baseline at week 16 compared to patients on placebo, who achieved − 12.2 (p < 0.01).

Conclusion

Despite having high QoL impairment at baseline, patients with itch-dominant AD treated with BARI 4 mg showed marked benefits in QoL, daily life activity, and work function compared to placebo after 16 weeks of treatment. Limitations include the small sample size analyzed.
Literature
2.
go back to reference Paul C, et al. Factors predicting quality of life impairment in adult patients with atopic dermatitis: results from a patient survey and machine learning analysis. Dermatol Ther (Heidelb). 2023;13(4):981–95. Paul C, et al. Factors predicting quality of life impairment in adult patients with atopic dermatitis: results from a patient survey and machine learning analysis. Dermatol Ther (Heidelb). 2023;13(4):981–95.
3.
go back to reference Lio PA, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943–8.CrossRefPubMed Lio PA, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943–8.CrossRefPubMed
4.
go back to reference Silverberg JI, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–7.CrossRefPubMed Silverberg JI, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–7.CrossRefPubMed
5.
go back to reference Sims JT, et al. Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease. Exp Dermatol. 2021;30(11):1650–61.CrossRefPubMedPubMedCentral Sims JT, et al. Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease. Exp Dermatol. 2021;30(11):1650–61.CrossRefPubMedPubMedCentral
6.
go back to reference Lio PA, et al. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy. J Dermatolog Treat. 2022;33(4):2057–62.CrossRefPubMed Lio PA, et al. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy. J Dermatolog Treat. 2022;33(4):2057–62.CrossRefPubMed
8.
go back to reference Chovatiya R, et al. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127(1):83-90.e2.CrossRefPubMed Chovatiya R, et al. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127(1):83-90.e2.CrossRefPubMed
9.
go back to reference Thyssen JP, et al. Baseline body surface area and itch severity define response to baricitinib in patients with moderate-to-severe atopic dermatitis at week 16. Adv Ther. 2023;40(8):3574–87.CrossRefPubMedPubMedCentral Thyssen JP, et al. Baseline body surface area and itch severity define response to baricitinib in patients with moderate-to-severe atopic dermatitis at week 16. Adv Ther. 2023;40(8):3574–87.CrossRefPubMedPubMedCentral
11.
go back to reference Katoh N, et al. Pooled safety analysis of baricitinib in adult participants with atopic dermatitis in the Japanese subpopulation from six randomized clinical trials. Dermatol Ther. 2022;12(12):2765–79. Katoh N, et al. Pooled safety analysis of baricitinib in adult participants with atopic dermatitis in the Japanese subpopulation from six randomized clinical trials. Dermatol Ther. 2022;12(12):2765–79.
12.
go back to reference Carrascosa J-M, et al. Baricitinib improvement across regions in atopic dermatitis patients with baseline body surface area up to 40% and severe itch. Dermatol Ther. 2024;14(6):1561–73. Carrascosa J-M, et al. Baricitinib improvement across regions in atopic dermatitis patients with baseline body surface area up to 40% and severe itch. Dermatol Ther. 2024;14(6):1561–73.
13.
go back to reference Reich K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–43.CrossRefPubMed Reich K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–43.CrossRefPubMed
14.
go back to reference De Bruin-Weller M, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2): adv00402. De Bruin-Weller M, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2): adv00402.
15.
go back to reference Costanzo A, et al. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Ital J Dermatol Venerol. 2022;157(1):1–12.PubMed Costanzo A, et al. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Ital J Dermatol Venerol. 2022;157(1):1–12.PubMed
16.
go back to reference Wollenberg A, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial. J Eur Acad Dermatol Venereol. 2021;35(7):1543–52. Wollenberg A, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial. J Eur Acad Dermatol Venereol. 2021;35(7):1543–52.
17.
go back to reference Hongbo Y, et al. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–64.CrossRefPubMed Hongbo Y, et al. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–64.CrossRefPubMed
18.
go back to reference Yosipovitch G, et al. The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials. Br J Dermatol. 2022;186(6):1047–9.CrossRefPubMedPubMedCentral Yosipovitch G, et al. The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials. Br J Dermatol. 2022;186(6):1047–9.CrossRefPubMedPubMedCentral
Metadata
Title
Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch
Authors
Matthias Augustin
Maddalena Napolitano
Rosa Izu-Belloso
C. Elise Kleyn
Silvia Sabatino
Susanne Grond
Joaquin R. Otero-Asman
Chunyuan Liu
Ziad Reguiai
Toshifumi Nomura
Publication date
29-01-2025
Publisher
Springer Healthcare
Published in
Dermatology and Therapy
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-024-01330-w

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more